FR2189034A2 - - Google Patents

Info

Publication number
FR2189034A2
FR2189034A2 FR7321743A FR7321743A FR2189034A2 FR 2189034 A2 FR2189034 A2 FR 2189034A2 FR 7321743 A FR7321743 A FR 7321743A FR 7321743 A FR7321743 A FR 7321743A FR 2189034 A2 FR2189034 A2 FR 2189034A2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7321743A
Other languages
French (fr)
Other versions
FR2189034B2 (2
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Laboratories Ltd
Original Assignee
Glaxo Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Laboratories Ltd filed Critical Glaxo Laboratories Ltd
Publication of FR2189034A2 publication Critical patent/FR2189034A2/fr
Application granted granted Critical
Publication of FR2189034B2 publication Critical patent/FR2189034B2/fr
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
FR7321743A 1972-06-15 1973-06-14 Expired FR2189034B2 (2)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2811872A GB1434919A (en) 1972-06-15 1972-06-15 3alpha-hydroxy androstanes

Publications (2)

Publication Number Publication Date
FR2189034A2 true FR2189034A2 (2) 1974-01-25
FR2189034B2 FR2189034B2 (2) 1977-01-21

Family

ID=10270562

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7321743A Expired FR2189034B2 (2) 1972-06-15 1973-06-14

Country Status (9)

Country Link
BE (1) BE800899R (2)
CA (1) CA1040619A (2)
DE (1) DE2330342A1 (2)
DK (1) DK136157B (2)
FR (1) FR2189034B2 (2)
GB (1) GB1434919A (2)
LU (1) LU67790A1 (2)
NL (1) NL7308267A (2)
ZA (1) ZA734037B (2)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス, インコーポレイテッド 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2015010054A2 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2848823T3 (es) 2013-08-23 2021-08-12 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016123056A1 (en) 2015-01-26 2016-08-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP4155314A1 (en) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH273860A (de) * 1942-04-25 1951-02-28 Nv Organon Verfahren zur Herstellung einer im Ring C eine sauerstoffhaltige Gruppe enthaltenden Verbindung der Cyclopentanopolyhydrophenanthren-Reihe.
FR2118117A1 (2) * 1970-12-17 1972-07-28 Glaxo Lab Ltd
FR2118123A1 (2) * 1970-12-17 1972-07-28 Glaxo Lab Ltd

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH273860A (de) * 1942-04-25 1951-02-28 Nv Organon Verfahren zur Herstellung einer im Ring C eine sauerstoffhaltige Gruppe enthaltenden Verbindung der Cyclopentanopolyhydrophenanthren-Reihe.
FR2118117A1 (2) * 1970-12-17 1972-07-28 Glaxo Lab Ltd
FR2118123A1 (2) * 1970-12-17 1972-07-28 Glaxo Lab Ltd

Also Published As

Publication number Publication date
DE2330342A1 (de) 1974-01-17
BE800899R (fr) 1973-12-14
DK136157B (da) 1977-08-22
GB1434919A (en) 1976-05-12
DK136157C (2) 1978-01-23
LU67790A1 (2) 1973-08-16
ZA734037B (en) 1974-05-29
NL7308267A (2) 1973-12-18
CA1040619A (en) 1978-10-17
FR2189034B2 (2) 1977-01-21
AU5693773A (en) 1974-12-19

Similar Documents

Publication Publication Date Title
AU5289373A (2)
CH564865A5 (2)
CH565560A5 (2)
BG18232A1 (2)
BG18502A1 (2)
BG18751A1 (2)
BG20209A1 (2)
CH565276A (2)
BG21228A3 (2)
BG21608A3 (2)
CH545531A (2)
CH545899A (2)
CH545919A (2)
CH559186A5 (2)
CH559314A5 (2)
CH560639A5 (2)
CH561531A5 (2)
CH561802A5 (2)
CH561826A5 (2)
CH561994A5 (2)
CH562000A5 (2)
CH562099A5 (2)
CH562113A5 (2)
CH562325A5 (2)
CH562336A5 (2)